TG Therapeutics Inc annual ebitda for fiscal 2025 was $134 million, an increase of 168.0% from $50 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | — | $134M | $50M | $26M | ($213M) | ($342M) | ($273M) | ($167M) | ($173M) | ($119M) | ($79M) | ($63M) | ($56M) | ($20M) | ($25M) | ($1M) | $2M | ($2M) | ($4M) | ($12M) | ($10M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| EBITDA | — | $28M | $52M | $33M | $38M | $12M | $33M | $15M | $11M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More TGTX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All TGTX financial statements → Interactive TGTX charts →
About TickerBase · Data methodology & sources · Privacy · Terms